Researchers have identified a potential therapeutic option for long COVID sufferers experiencing debilitating fatigue. A randomized clinical trial encompassing 399 adults found that fluvoxamine, an inexpensive antidepressant medication, substantially lessened fatigue symptoms and enhanced overall quality of life compared to placebo treatment.
The findings represent a significant development in addressing long COVID, a condition that has affected millions worldwide with persistent and often severe fatigue. Fluvoxamine emerges as among the first pharmacological interventions to demonstrate clinically meaningful improvements for patients dealing with this challenging post-viral syndrome.
More Stories
Penn State Engineers Develop Paint-On Electronic Tattoo for Heart Monitoring
DNA Study Reveals Medieval Tombs at Barcelona Monastery Contain Wrong Remains
Excessive Television Viewing in Middle Age Linked to Brain Shrinkage Later in Life